<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[RSS Feed]]></title><description><![CDATA[RSS Feed]]></description><link>http://direct.ecency.com</link><image><url>http://direct.ecency.com/logo512.png</url><title>RSS Feed</title><link>http://direct.ecency.com</link></image><generator>RSS for Node</generator><lastBuildDate>Fri, 01 May 2026 13:17:54 GMT</lastBuildDate><atom:link href="http://direct.ecency.com/created/thasso/rss.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Febuxostat (Uloric) and its problem with cardiovascular mortality]]></title><description><![CDATA[Despite drug safety problems of cardiovascular mortality with Febuxostat (Uloric), the benefits might still be seen to outweigh risks for selected gout patients. This notion may become more and more disputed,]]></description><link>http://direct.ecency.com/theragenomics/@gut50/febuxostat-uloric-and-its-problem-with-cardiovascular-mortality</link><guid isPermaLink="true">http://direct.ecency.com/theragenomics/@gut50/febuxostat-uloric-and-its-problem-with-cardiovascular-mortality</guid><category><![CDATA[theragenomics]]></category><dc:creator><![CDATA[gut50]]></dc:creator><pubDate>Thu, 16 May 2019 14:49:06 GMT</pubDate></item></channel></rss>